Motco boosted its position in shares of Eli Lilly And Co (NYSE:LLY) by 10.8% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 51,242 shares of the company’s stock after acquiring an additional 5,009 shares during the period. Motco’s holdings in Eli Lilly And Co were worth $5,730,000 at the end of the most recent quarter.
A number of other institutional investors have also recently added to or reduced their stakes in LLY. Carillon Tower Advisers Inc. increased its holdings in shares of Eli Lilly And Co by 685.1% during the 3rd quarter. Carillon Tower Advisers Inc. now owns 166,439 shares of the company’s stock worth $18,613,000 after purchasing an additional 145,239 shares during the period. Principle Wealth Partners LLC bought a new position in shares of Eli Lilly And Co during the 3rd quarter worth about $275,000. Sector Gamma AS bought a new position in shares of Eli Lilly And Co during the 3rd quarter worth about $17,010,000. Arthur M. Cohen & Associates LLC increased its holdings in shares of Eli Lilly And Co by 2.8% during the 3rd quarter. Arthur M. Cohen & Associates LLC now owns 48,180 shares of the company’s stock worth $5,388,000 after purchasing an additional 1,307 shares during the period. Finally, Bingham Osborn & Scarborough LLC bought a new position in shares of Eli Lilly And Co during the 3rd quarter worth about $203,000. 77.22% of the stock is owned by hedge funds and other institutional investors.
NYSE LLY traded down $0.89 on Monday, reaching $112.64. The company’s stock had a trading volume of 65,284 shares, compared to its average volume of 7,683,282. The firm has a market cap of $106.81 billion, a PE ratio of 20.26, a price-to-earnings-growth ratio of 1.82 and a beta of 0.16. The business has a 50-day moving average price of $110.61 and a 200 day moving average price of $112.67. Eli Lilly And Co has a 52 week low of $101.36 and a 52 week high of $132.13. The company has a current ratio of 1.17, a quick ratio of 0.88 and a debt-to-equity ratio of 4.09.
Eli Lilly And Co (NYSE:LLY) last posted its earnings results on Wednesday, October 23rd. The company reported $1.48 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.43 by $0.05. The business had revenue of $5.48 billion for the quarter, compared to analysts’ expectations of $5.50 billion. Eli Lilly And Co had a net margin of 35.10% and a return on equity of 107.99%. The firm’s revenue for the quarter was up 3.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.39 earnings per share. Analysts anticipate that Eli Lilly And Co will post 5.78 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Friday, November 15th will be paid a $0.645 dividend. The ex-dividend date is Thursday, November 14th. This represents a $2.58 dividend on an annualized basis and a yield of 2.29%. Eli Lilly And Co’s payout ratio is currently 46.49%.
LLY has been the topic of several research reports. UBS Group dropped their price objective on shares of Eli Lilly And Co from $134.00 to $133.00 and set a “buy” rating on the stock in a report on Thursday, October 17th. Bank of America initiated coverage on shares of Eli Lilly And Co in a report on Wednesday, October 16th. They set a “buy” rating and a $133.00 price objective on the stock. Six investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Eli Lilly And Co presently has a consensus rating of “Buy” and a consensus price target of $130.03.
In other Eli Lilly And Co news, major shareholder Lilly Endowment Inc sold 173,918 shares of the company’s stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $114.05, for a total transaction of $19,835,347.90. Following the sale, the insider now directly owns 116,229,383 shares of the company’s stock, valued at $13,255,961,131.15. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Stephen F. Fry sold 9,452 shares of the company’s stock in a transaction dated Thursday, September 5th. The stock was sold at an average price of $115.00, for a total transaction of $1,086,980.00. Following the sale, the senior vice president now directly owns 100,211 shares in the company, valued at $11,524,265. The disclosure for this sale can be found here. In the last three months, insiders purchased 8,405 shares of company stock worth $909,004 and sold 614,373 shares worth $70,546,895. Insiders own 0.11% of the company’s stock.
Eli Lilly And Co Company Profile
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Recommended Story: What is Cost of Debt?
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.